TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04921046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lignocaine
Description: After giving lignocaine to a group of people, myoclonus was observed after the dose of etomidate given two minutes after lignocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 1 milligram Prefilled Syringe
Description: after giving midazolam to the second group of people two minutes before etomidate dose, myoclonus was observed for one minute.
Study: NCT01981629

Intervention type: DEVICE
Intervention: USCOM
Description: The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
Study: NCT03174041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Multiple doses GDC-0853 for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Multiple doses GDC-0853 for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Multiple doses GDC-0853 for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and GDC-0853
Description: Multiple doses GDC-0853 and single dose midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single dose rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and GDC-0853
Description: Multiple doses GDC-0853 and single dose rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Single dose simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin and GDC-0853
Description: Multiple doses GDC-0853 and single dose simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Single dose GDC-0853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple doses itraconazole for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853 and itraconazole
Description: Multiple doses itraconazole and single dose GDC-0853
Study: NCT03216200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plasma treatment
Description: application of cold atmospheric plasma to a fungal infected toenail
Study: NCT01294839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right ventricular lead location
Description: RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular lead location
Description: RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Right ventricular lead location
Description: RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
Study: NCT01886677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate diet and exercise intervention
Description: Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed diet and exercise intervention
Description: Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
Study: NCT04553822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted autogenous drainage group (DAA)
Description: DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group prolonged slow expiration (ELPr)
Description: Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
Study: NCT00616928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: Two intramuscular injections at Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: Two intramuscular injections at Days 0 and 21.
Study: NCT04553822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group (CG)
Description: Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
Study: NCT04232865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biop System
Description: Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa.
Study: NCT04751552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (for postoperative pain relief)
Description: A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane Block (for postoperative pain relief)
Description: A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
Study: NCT05793164

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03489642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Program
Description: Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
Study: NCT03493854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
Study: NCT01761435

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.
Study: NCT01263743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response
Description: The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response
Description: Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
Study: NCT03399760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: i-PRF (injectable platelet rich fibrin) assisted upper canine retraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: canine retraction
Description: upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
Study: NCT00803647

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
Study: NCT03631186

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT03706599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education on fever
Description: Session for therapeutique education on fever

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic education on household accidents
Description: Session for therapeutic education on household accidents
Study: NCT00706121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU daily by mouth for 7 - 12 years
Study: NCT00616928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: Two intramuscular injections at Days 0 and 21.
Study: NCT00706121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU daily by mouth for 7 - 12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 mcg daily for 7 - 12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 mcg daily for 7 - 12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E placebo
Description: 1 pill by mouth daily for 7 - 12 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E placebo
Description: 1 pill by mouth daily for 7 - 12 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: 1 pill by mouth daily for 7 - 12 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selenium placebo
Description: 1 pill by mouth daily for 7 - 12 years
Study: NCT03049046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC100
Description: synthetic caffeic acid phenethylester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC100
Description: synthetic caffeic acid phenethylester

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC100
Description: synthetic caffeic acid phenethylester

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Diluent
Study: NCT02323919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SystemCHANGE
Description: consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHANGE+
Description: consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
Study: NCT00280332

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: proform a follow up colonoscopy in the 5 year period from index colonoscopy

Intervention type: PROCEDURE
Intervention: colonoscopy
Description: proform a follow up colonoscopy in the 5 year period from index colonoscopy
Study: NCT01540123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry drink
Description: Cold pressed berry drink standardised to contain 500mg of berry polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sugar matched control containing berry flavouring and no phytochemicals
Study: NCT02575092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate Tablets(as the program-based antihypertension)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00725166

Intervention type: OTHER
Intervention: Skeletal muscle aging
Description: W1 - Blood test~* Maximal voluntary contraction of quadriceps~* Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy
Study: NCT00616928

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intramuscular injections at Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intramuscular injections at Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intramuscular injections at Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intramuscular injections at Days 0 and 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two intramuscular injections at Days 0 and 21.
Study: NCT02516631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angusta™
Description: One tablet of Angusta™ (25 µg) given every 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec®
Description: 1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angusta™
Description: Two tablets of Angusta™ 25 µg given every 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec®
Description: ¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angusta™
Description: Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec®
Description: ¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
Study: NCT01001871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles®
Description: powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin/mineral fortificant without iron
Description: powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
Study: NCT01341522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI exam
Description: MRI exam

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: waiting room
Study: NCT04451382

Intervention type: BIOLOGICAL
Intervention: OnabotulinumtoxinA (BoNTA)

Intervention type: PROCEDURE
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Study: NCT01736137

Intervention type: OTHER
Intervention: Six minute walk test
Description: If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).

Intervention type: OTHER
Intervention: Six minute walk test
Description: If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
Study: NCT02236156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Study: NCT00371488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016 oral tablets
Description: Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
Study: NCT04032275

Intervention type: OTHER
Intervention: Chronic hepatitis B infection
Description: Chronic hepatitis B infection patients
Study: NCT03063489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Ophthalmic Gel
Description: Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])
Study: NCT01888328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg